BioPharmSignal logoBioPharmSignal

Biotech News

Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy

Virios Therapeutics (VIRI)Virios TherapeuticsFDA / regulatory

VIRI (VIRI) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is viri.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

VIRIVirios Therapeutics2026-08-17 12:30 EST

Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026

VIRIVirios Therapeutics2026-05-18 12:45 EST

Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study

ABUSArbutus2026-04-15 11:30 EST

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

COCPCocrystal Pharma2026-04-02 12:00 EST

Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive

OGENOragenics2026-03-10 12:30 EST

Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia

SPROSpero Therapeutics2026-06-17 17:36 EST

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

ENTAEnanta Pharmaceuticals2026-06-23 09:10 EST

Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus

MBRXMoleculin Biotech, Inc.2026-02-19 13:39 EST

Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds

AVIRAtea2026-05-27 11:00 EST

Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026

ANTXAN2 Therapeutics2026-08-31 22:00 EST

AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

View all latest news

Virios Therapeutics

Non-Opioid Pain Company Dogwood Therapeutics, formerly Virios Therapeutics, develops non-opioid medicines for pain and neuropathy. Halneuron Halneuron is an investigational non-opioid analgesic being evaluated for chemotherapy-induced neuropathic pain. The program is designed to provide durable pain reduction without the risks associated...

Recent company news

VIRIVirios Therapeutics2026-09-14 12:45 EST

Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial

VIRIVirios Therapeutics2026-08-17 12:30 EST

Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026

VIRIVirios Therapeutics2026-08-13 12:30 EST

Dogwood Therapeutics Announces Second Quarter 2026 Financial Results

VIRIVirios Therapeutics2026-07-20 12:30 EST

Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026

VIRIVirios Therapeutics2026-06-30 12:45 EST

Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States